Environmental persistent pharmaceutical pollutant

• Environmental Persistent Pharmaceutical Pollutants (EPPPs) refer to a subset of pharmaceutical compounds that, due to their chemical properties and persistence, have the potential to accumulate in the environment over time.
• These pollutants have raised significant concerns due to their adverse effects on aquatic ecosystems, human health, and the potential for the development of antimicrobial resistance.
• The term Environmental persistent pharmaceutical pollutants (EPPP) was first suggested in the nomination in 2010 of pharmaceuticals and environment as an emerging issue in a Strategic Approach to International Chemicals Management (SAICM) by the International Society of Doctors for the Environment (ISDE).
• The occurring problems from EPPPs are in parallel explained under environmental impact of pharmaceuticals and personal care products (PPCP).
• The European Union summarizes pharmaceutical residues with the potential of contamination of water and soil together with other micropollutants under “priority substances”.

Pharmaceutical pollution of the world's rivers – sampling sites

Sources of EPPPs

• EPPPs enter the environment through various pathways:

1. Wastewater Discharge

• Pharmaceutical residues from human excretion, unused medications, and improper disposal can find their way into wastewater treatment systems.
• Conventional wastewater treatment processes are often insufficient in removing EPPPs, leading to their release into water bodies.

2. Livestock and Agriculture

• The use of pharmaceuticals in livestock and aquaculture can result in the release of EPPPs into the environment through animal waste and runoff.

3. Aquatic Disposal

• Improper disposal of unused or expired medications into toilets or sinks contributes to the presence of EPPPs in water bodies.

4. Industrial Effluents

• Pharmaceutical manufacturing processes and pharmaceutical industries may release EPPPs into the environment through industrial effluents.

Environmental Fate and Impact

• EPPPs pose a range of environmental and human health risks:

1. Ecotoxicity

• EPPPs can disrupt aquatic ecosystems by affecting the behavior, physiology, and reproduction of aquatic organisms.
• They may accumulate in aquatic food chains, potentially impacting higher trophic levels.

2. Antimicrobial Resistance

• The presence of pharmaceutical residues in the environment may contribute to the development of antimicrobial resistance in bacteria, compromising the effectiveness of antibiotics.

3. Human Exposure

• EPPPs can find their way into drinking water sources, potentially leading to human exposure.
• Long-term exposure to low levels of these pollutants may have subtle yet significant health implications.

4. Ecosystem Disruption

• The accumulation of EPPPs can disrupt the balance of aquatic ecosystems, affecting biodiversity and ecosystem services.

Mitigation Strategies

• Addressing the issue of EPPPs requires a multi-pronged approach:

1. Improved Wastewater Treatment

• Advanced treatment technologies, such as activated carbon filtration and ozonation, can enhance the removal of EPPPs from wastewater.

2. Pharmaceutical Disposal Guidelines

• Educating the public about proper disposal methods for unused medications can prevent the entry of EPPPs into water bodies.

3. Regulation and Policy

• Stringent regulations and policies regarding pharmaceutical manufacturing, use, and disposal can help minimize the release of EPPPs into the environment.

4. Green Pharmacy Practices

• Pharmaceutical manufacturers can adopt environmentally friendly production methods, including green chemistry principles, to reduce the generation of EPPPs.

5. Public Awareness and Education

• Raising awareness among healthcare professionals, patients, and the public about the environmental impacts of pharmaceuticals can promote responsible use and disposal.

Conclusion

• Environmental Persistent Pharmaceutical Pollutants (EPPPs) represent a growing environmental concern with potential implications for ecosystems and human health.
• The accumulation of these persistent compounds in water bodies can disrupt aquatic ecosystems, contribute to antimicrobial resistance, and pose risks to human populations.
• To address this issue, collaborative efforts among regulatory agencies, industries, healthcare providers, and the public are essential.
• By implementing improved wastewater treatment methods, promoting responsible pharmaceutical disposal, and adopting sustainable production practices, society can work together to minimize the environmental impact of EPPPs and safeguard aquatic ecosystems for future generations.

References

• Bound, J. P., & Voulvoulis, N. (2005). Pharmaceuticals in the aquatic environment—a comparison of risk assessment strategies. Chemosphere, 58(11), 1471-1486.
• Boxall, A. B. (2004). The environmental side effects of medication. EMBO reports, 5(S1), S111-S115.
• Fick, J., Söderström, H., Lindberg, R. H., Phan, C., Tysklind, M., & Larsson, D. G. (2009). Contamination of surface, ground, and drinking water from pharmaceutical production. Environmental toxicology and chemistry, 28(12), 2522-2527.

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia